chr4-72128592-A-G
Position:
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PVS1PM2
The NM_004885.3(NPFFR2):āc.1A>Gā(p.Met1?) variant causes a start lost change. The variant allele was found at a frequency of 0.0000163 in 1,593,820 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Genomes: š 0.000026 ( 0 hom., cov: 30)
Exomes š: 0.000015 ( 0 hom. )
Consequence
NPFFR2
NM_004885.3 start_lost
NM_004885.3 start_lost
Scores
2
7
10
Clinical Significance
Conservation
PhyloP100: 6.35
Genes affected
NPFFR2 (HGNC:4525): (neuropeptide FF receptor 2) This gene encodes a member of a subfamily of G-protein-coupled neuropeptide receptors. This protein is activated by the neuropeptides A-18-amide (NPAF) and F-8-amide (NPFF) and may function in pain modulation and regulation of the opioid system. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jan 2009]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 10 ACMG points.
PVS1
Start lost variant, no new inframe start found.
PM2
Very rare variant in population databases, with high coverage;
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NPFFR2 | NM_004885.3 | c.1A>G | p.Met1? | start_lost | 2/4 | ENST00000308744.12 | NP_004876.3 | |
NPFFR2 | NM_053036.3 | c.1A>G | p.Met1? | start_lost | 2/4 | NP_444264.1 | ||
NPFFR2 | NM_001144756.2 | c.10A>G | p.Met4Val | missense_variant | 3/5 | NP_001138228.1 | ||
NPFFR2 | XM_011531554.3 | c.305-9448A>G | intron_variant | XP_011529856.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
NPFFR2 | ENST00000308744.12 | c.1A>G | p.Met1? | start_lost | 2/4 | 1 | NM_004885.3 | ENSP00000307822.7 | ||
NPFFR2 | ENST00000358749.3 | c.1A>G | p.Met1? | start_lost | 2/4 | 1 | ENSP00000351599.3 | |||
NPFFR2 | ENST00000395999.5 | c.10A>G | p.Met4Val | missense_variant | 3/5 | 1 | ENSP00000379321.1 | |||
NPFFR2 | ENST00000344413.6 | c.-20-9448A>G | intron_variant | 1 | ENSP00000340789.6 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152222Hom.: 0 Cov.: 30
GnomAD3 genomes
AF:
AC:
4
AN:
152222
Hom.:
Cov.:
30
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000288 AC: 7AN: 242808Hom.: 0 AF XY: 0.0000305 AC XY: 4AN XY: 131308
GnomAD3 exomes
AF:
AC:
7
AN:
242808
Hom.:
AF XY:
AC XY:
4
AN XY:
131308
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000153 AC: 22AN: 1441598Hom.: 0 Cov.: 29 AF XY: 0.0000126 AC XY: 9AN XY: 715514
GnomAD4 exome
AF:
AC:
22
AN:
1441598
Hom.:
Cov.:
29
AF XY:
AC XY:
9
AN XY:
715514
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152222Hom.: 0 Cov.: 30 AF XY: 0.0000269 AC XY: 2AN XY: 74364
GnomAD4 genome
AF:
AC:
4
AN:
152222
Hom.:
Cov.:
30
AF XY:
AC XY:
2
AN XY:
74364
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
3
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 07, 2024 | The c.307A>G (p.M103V) alteration is located in exon 2 (coding exon 2) of the NPFFR2 gene. This alteration results from a A to G substitution at nucleotide position 307, causing the methionine (M) at amino acid position 103 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Uncertain
D
BayesDel_noAF
Pathogenic
CADD
Benign
DANN
Uncertain
DEOGEN2
Benign
T;.;.
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Pathogenic
D
LIST_S2
Benign
T;T;D
M_CAP
Benign
D
MetaRNN
Uncertain
D;D;D
MetaSVM
Uncertain
T
MutationAssessor
Benign
N;.;.
PrimateAI
Benign
T
PROVEAN
Benign
N;N;N
REVEL
Uncertain
Sift
Benign
T;D;D
Sift4G
Benign
T;.;D
Polyphen
D;D;.
Vest4
MutPred
Loss of disorder (P = 0.1133);.;.;
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at